Home › Endometrial Cancer › Rhode Island
Endometrial Cancer clinical trials in Rhode Island
15 studies for Endometrial Cancer are looking for participants at sites in Rhode Island.
Cities in Rhode Island
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 30, 2026 · NCT07198074Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
- Women and Infants Hospital, Providence
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05256225Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
RecruitingPhase 2
All ages · All sexes · Updated Sep 29, 2026 · NCT05564377Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Women and Infants Hospital, Providence
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Women and Infants Hospital, Providence
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Women & Infants Hospital ( Site 5003), Providence
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Women & Infants Hospital of Rhode Island, Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06515613Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Women and Infants Hospital, Providence
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT05950464DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Providence
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Women & Infants Hospital, Providence
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Providence
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 21, 2026 · NCT05797168Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2025 · NCT05997017A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.